Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiotoxicity comparison of R-CHOP versus R-COMP in diffuse large B-cell lymphoma
2007-004970-24Phase 2Completed
- Sponsor
- AGMT
- Start
- Dec 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of doxorubicin and pegylated liposomal doxorubicin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AGMT. Primary endpoints: NT-proBNP level and Left ventricular ejection fraction. Started Dec 2007; status: completed.
02
Drugs
doxorubicinpegylated liposomal doxorubicin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2007-004970-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004970-24.